In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...
The FDA agreed to review Moderna’s experimental mRNA influenza vaccine after Moderna resubmitted its application with modifications.
Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced ...
The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...
The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results